SCHEMBL7964187

SCHEMBL7964187

Cc1ccc(C#N)cc1BO

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP2A6 P11509 2/20 0.41
▸ ALDH1A1 P00352 1/20 0.41
▸ FFAR1 O14842 2/20 0.37
▸ CA12 O43570 1/20 0.37
▸ CA2 P00918 1/20 0.37
▸ CA3 P07451 1/20 0.37
▸ CA6 P23280 1/20 0.37
▸ CA9 Q16790 1/20 0.37
▸ CA14 Q9ULX7 1/20 0.37
▸ AR P10275 4/20 0.36
▸ TSHR P16473 1/20 0.34
▸ CYP11B1 P15538 1/20 0.34
▸ CYP11B2 P19099 1/20 0.34
▸ EGLN2 Q96KS0 1/20 0.34
▸ ENPP2 Q13822 2/20 0.33
▸ FFAR4 Q5NUL3 1/20 0.33
▸ MMP3 P08254 1/20 0.33
▸ NOS3 P29474 1/20 0.33
▸ NOS1 P29475 1/20 0.33
▸ TP53 P04637 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8879327 0.82 CYP2A6 (0.43) CYP2A6ALDH1A1FFAR1CA12CA2
SCHEMBL29814587 0.73 CYP2A6 (0.52) CYP2A6ALDH1A1FFAR1CA12CA2
SCHEMBL1436903 0.73 CYP2A6 (0.52) CYP2A6ALDH1A1FFAR1CA12CA2
SCHEMBL31294509 0.72 TSHR (0.46) CYP2A6ALDH1A1FFAR1CA12CA2
SCHEMBL68647 0.72 TSHR (0.46) CYP2A6ALDH1A1FFAR1CA12CA2
SCHEMBL2409646 0.72 TDP1 (0.42) CYP2A6ALDH1A1TP53
SCHEMBL17796286 0.70 CYP2A6 (0.48) CYP2A6ALDH1A1FFAR1CA12CA2
SCHEMBL1003188 0.70 TSHR (0.50) CYP2A6ALDH1A1FFAR1CA12CA2
SCHEMBL31555022 0.69 ENPP2 (0.48) CYP2A6ALDH1A1FFAR1CA12CA2
SCHEMBL16958326 0.69 CYP2A6 (0.43) CYP2A6ALDH1A1FFAR1CA12CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2010021680-A2 INHIBITORS OF BETA-SECRETASE VITAE PHARMACEUTICALS, INC. (US) 2010-02-25 — — WO disclosed
Send feedback